

References

REFERENCES

Abdel-Aziz F, Habib M and Mohamed M (2000): Hepatitis C virus (HCV) infection in a community in the Nile Delta: population description and HCV prevalence. *Hepatology*, 32: 111-15.

Alter MJ, Kuhnert WL and Finelli L (2003): Guidelines for laboratory testing and result reporting of antibody to hepatitis C virus. Centers for Disease Control and Prevention. *MMWR Recomm Rep* ; 52: 1-13, 15

Alter MJ, Kurszon-Moran D and Nainan OV (1999): The prevalence of hepatitis C virus in the united states, 1988 through 1994 *N. Engl.J. Med*, 341(8):556-57

Alter MJ, Seeff LB, Bacon BR, Thomas DL, Rigsby MO and Di Bisceglie AM (2004): Testing for hepatitis C virus infection should be routine for persons at increased risk for infection. *Ann Intern Med* 141: 715-717.

Al-Quaiz M, Madani T and Karawi M (2003): The natural history of hepatitis C virus infection. *Saudi Med J*, 24(2):67-70.

Anthony PP, Ishak KG, Nayak NC, Poulsen HE, Scheuer PJ, and Sobin LH. (1978): The morphology of cirrhosis. Recommendations on definition, nomenclature, and classification by a working group sponsored by the World Health Organization. *J Clin Pathol* 1978;31:395-414.

Arafa N, El-Hoseiny M, Rekaowicz C (2005): Changing pattern of HCV spread in rural areas in Egypt. *J Hepatol*, 43: 418-24

Arena U, Vizzutti F, Corti G, Ambu S, Stasi C and Bresci S (2008): Acute viral hepatitis increases liver stiffness values measured by transient elastography. *Hepatology* 47: 380–384.

Arey LB, Burrows W, Greenhill JP and Hewitt RM (1962): Dorland's illustrated medical dictionary 23rd edition. Philadelphia: Press of W.B Saunders Company;1962:286.

Axelsson J, Bergsten A and Qureshi AR (2006): Elevated resistin levels in chronic kidney disease are associated with decreased glomerular filtration rate and inflammation, but not with insulin resistance. *Kidney Int.* 69:596-604.

Bacon R, O'Grady J, Di Bisceglie A and Lake J (2006): Comprehensive Clinical Hepatology. Second edition p244

Bahr M, Ockenga J, Böker K, Manns M and Tietge U (2006): Elevated resistin levels in cirrhosis are associated with the proinflammatory state and altered hepatic glucose metabolism but not with insulin resistance. *Am J Physiol Endocrinol Metab.* 2006 Aug; 291(2):E199-206.

Bajaj M, Suraamornkul S, Hardies LJ, Pratipanawat T, DeFronzo RA (2004): Plasma resistin concentration, hepatic fat content, and hepatic and peripheral insulin resistance in pioglitazone-treated type II diabetic patients. *Int J Obes Relat Metab Disord* 28:783–789

Banerjee R. R. and Lazar M (2001): Dimerization of resistin and resistin-like molecules is determined by a single cysteine. *J. Biol. Chem.* 276, 25970

Bedossa P, Dargere D and Paradis V. (2003): Sampling variability of liver fibrosis in chronic hepatitis C. *Hepatology* 38: 1449–57 .

Bertolani Cristiana, Pau Sancho-Bru, Paola Failli, Ramon Bataller, Sara Aleffi, Raffaella DeFranco, Benedetta Mazzeinghi, Paola Romagnani, Stefano Milani, Pere Ginés, Jordi Colmenero, Maurizio Parola, Stefania Gelmini, Roberto Tarquini, Giacomo Laffi, Massimo Pinzani and Fabio Marra (2006): *American Journal of Pathology.* 2006;169:2042-2053.

Bokarewa M, Nagaev I, Dahlberg L, Smith U and Tarkowski A (2005): Resistin, an Adipokine with Potent Proinflammatory Properties. *The Journal of Immunology*, 2005, 174:5789-5795

Boyer JL (2001): Liver cirrhosis and its development: proceedings of the Falk Symposium 115. Springer. pp. 344.

Buckwold V (2004): Implications of finding synergic in vitro drug-drug interactions between interferon-(alpha) and ribavirin for the treatment of hepatitis C virus. *J Antimicrob Chemother*, 53: 413-14.

Byung-Soo Youn, Kang-Yeol Yu, Hong Je Park, Nam Seok Lee, Sung Shik Min, Moon Yeon Youn, Young Min Cho, Young Joo Park, Seong Yeon Kim, Hong Kyu Lee and Kyong Soo Park. (2004): Plasma Resistin Concentrations Measured by Enzyme-Linked Immunosorbent Assay Using a Newly Developed Monoclonal Antibody Are Elevated in Individuals with Type 2 Diabetes Mellitus. *The Journal of Clinical Endocrinology & Metabolism*, vol. 89 no. 1 150-156

Campbell JV, Hagan H and Latka MH (2006): High prevalence of alcohol use among hepatitis C virus antibody positive injection drug users in three US cities. *Drug and Alcohol Dependence* 81 (3): 259–65.

Cárdenas A. (2005): Hepatorenal syndrome: A dreaded complication of end-stage liver disease. *Am J Gastroenterol* 100:460-467

Caruntu FA and Benea L (2006): Acute hepatitis C virus infection: Diagnosis, pathogenesis, treatment. *Journal of Gastrointestinal and Liver Diseases* 15 (3): 249–56.

Castera L, Vergniol J, Foucher J, Le Bail B, Chanteloup E and Haaser M (2005): Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. *Gastroenterology* 128: 343–350.

Cavalheiro N, Filgueiras T, Melo C, Morimitsu S, De Araújo E, F Tengan F and Barone A. (2007): Detection of HCV by PCR in Serum and PBMC of Patients with Hepatitis C After Treatment. *The Brazilian Journal of Infectious Diseases* 2007;11(5):471-474.

Chamberlain R, Adams N and Saeed A (1997): Complete nucleotide sequence of a type 4 hepatitis C virus variant, the predominant genotype in the Middle East. *J Gen Virol*, 78: 1341-47.

Chitturi S and Farrell GC (2001): Etiopathogenesis of nonalcoholic steatohepatitis. *Semin Liver Dis* 21:27-41

Clark JM. (2006): The epidemiology of nonalcoholic fatty liver disease in adults. *J Clin Gastroenterol* 2006; 40 (3 suppl 1): S5-10.

Conn HO (1975): Cirrhosis. In: *Diseases of the liver* 4th edition. Edited by Schiff L. Philadelphia: J.B. Lippincott Company;1975:833.

D'Amico G, Morabito A, Pagliaro L, Marubini E, and the liver study group of "V. Cervello" Hospital. (1986): Survival and prognostic indicators in compensated and decompensated cirrhosis. *Dig Dis Sci* 31:468-475.

De Franchis R. (2005): Evolving consensus in portal hypertension. Report of the Baveno IV consensus workshop on methodology of diagnosis and therapy in portal hypertension. *J Heptol* 2005;43:167-176.

Degawa-Yamauchi, M., Bovenkerk, J. E. and Juliar, B. E. (2003): Serum resistin (FIZZ3) protein is increased in obese humans. *J. Clin. Endocrinol. Metab.* 88, 5452-5455

Di Bisceglie, A (2000): Natural history of hepatitis C. *Hepatology* 31/4:1014-17

Di Bisceglie A (2006): Comprehensive clinical hepatology 1, second edition. Elsevier limited.

Di Lelio A, Cestari C, Lomazzi A and Beretta L.(1989): Cirrhosis: diagnosis with sonographic study of the liver surface. *Radiology*

Diehl AM (2002): Nonalcoholic steatosis and steatohepatitis. IV. Nonalcoholic fatty liver disease abnormalities in macrophage function and cytokines. *Am J Physiol* 282:G1–G5

Dienstag JL, Goldin RD and Heathcote EJ (2003): Histological outcome during long-term lamivudine therapy. *Gastroenterology* 124: 105–17 .

Dusheiko G, Nelson D and Reddy K. (2008): Ribavirin considerations in treatment optimization. *Antivir Ther*, 13 (1): 23-30.

Duffin JM. (1987): Why does cirrhosis belong to Laennec? *CMAJ* 1987;137:393-396

El-Raziky, M.S, Yousef, H, Salama, H.M, El Hawary, M, Salama, K and Abd El Moniem (2009): Adipokines in Chronic Liver Diseases; Role in Pediatric Patients. *Research Journal of Medicine and Medical Sciences*, 4(2): 428-434

Fishman J (2007): Infection in solid-organ transplantation. *Clin Microbiol Rev*, 21: 60-96.

Foy, E; Li, K; Wang, C; Sumpter, J; Ikeda, M and Lemon, M. (2003): Regulation of interferon regulatory factors 3 by the hepatitis C virus serine orotase. *Science* 300: 1145-1148

Frank C, Mohamed K and Strickland T (2000): The role of parenteral antischistosomal therapy in the spread of HCV in Egypt. *Lancet*, 355:887-891

Fujinami A, Obayashi H, Ohta K, Ichimura T, Nishimura M, Matsui H, Kawahara Y, Yamazaki M, Ogata M, Hasegawa G, Nakamura N, Yoshikawa T, Nakano K, Ohta M (2004): Enzyme-linked immunosorbent assay for circulating human resistin: resistin concentrations in normal subjects and patients with type 2 diabetes. *Clin Chim Acta* 339:57–63

Garfein R.S, Vlahav D and Galai N (1996): Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. *Am J Public Health*, 86: 655-71.

Geese, William J. and Ranade, Koustubh (2008): Method for identifying HIV-1 protease inhibitors with reduced metabolic effects. USPTO (WO/2008/005391) Publication No. US 2008/0004209

Goedert JJ, Chen BE, Preiss L, Aledort LM and Rosenberg PS. (2007): Reconstruction of the hepatitis C virus epidemic in the US hemophilia population, 1940-1990. *Am J Epidemiol* 165: 1443–1453.

Habib M, Mohamed MK and Abdel-Aziz F (2001): Hepatitis C virus infection in a community in the Nile Delta; risk factors for seropositivity. *Hepatology*, 33(1): 248-53.

Hampton Eric N., Mark W. KnuthJun Li, Jennifer L. Harris, Scott A. Lesley, and Glen Spraggon (2007): The self-inhibited structure of full-length PCSK9 at 1.9 Å reveals structural homology with resistin within the C-terminal domain *PNAS* September 11, 2007 vol. 104 no. 37 14604-14609

Haugen F, Zahid N, Dalen KT, Hollung K, Nebb HI and Drevon CA. (2005): Resistin expression in 3T3-L1 adipocytes is reduced by arachidonic acid. *J Lipid Res.* 46(1):143-53.

Heathcote E (2007): Antiviral therapy: chronic hepatitis C virus. *J Viral Hepat*, 14 (1): 82-8.

Heilbronn, L. K., Rood, J. and Janderoova, L. (2004): Relationship between serum resistin concentrations and insulin resistance in nonobese, obese, and obese diabetic subjects. *J. Clin. Endocrinol. Metab.* 89, 1844–1848

Henderson E. (2001): Physicians' Research Network Notebook, volume 6 Number 1

Hoeper MM, Krowka MJ and Strassburg CP. (2004): Portopulmonary hypertension and hepatopulmonary syndrome. *Lancet* 363:1461-1468.

Holcomb IN, Kabakoff RC, Chan B, Baker TW, Gurney A, Henzel W, Nelson C, Lowman HB, Wright BD, Skelton NJ, Frantz GD, Tumas DB, Peale FV Jr, Shelton DL

and Hébert CC (2000): FIZZ1, a novel cysteine-rich secreted protein associated with pulmonary inflammation, defines a new gene family". EMBO J. 19 (15): 4046–55.

Howdle PD (2000): Comprehensive Clinical Hepatology. Harcourt Publishers Limited 2000

Indolfi G, Azzari C and Moriondo M (2006): Alanine transaminase levels in the year before pregnancy predict the risk of hepatitis C virus vertical transmission. J Med Virol, 78: 911-14

Iredale JP. (2003): Cirrhosis: new research provides a basis for rational and targeted treatments. BMJ. Jul 19;327(7407):143-7.

Iredale JP and Guha IN. (2007): The evolution of cirrhosis. In: Textbook of hepatology from basic science to clinical practice. 3rd edition. Edited by Rodés J, Benhamou J-P, Blei A, Reichen J, Rizzetto M. Oxford, Blackwell Publishing 583-589

Jaeckel E, Cornberg M, Wedemeyer H, Santantonio T, Mayer J, Zankel M, Pastore G, Dietrich M, Trautwein C and Manns MP (2001): "Treatment of acute hepatitis C with interferon alfa-2b". New England Journal of Medicine 345 (20): 1452–1457.

Janke J, Engell S and Gorzeiniak K (2002): Resistin and gene expression in human adipocytes is not related to insulin resistance. Obesity research vol 10, 1-5

Kakizaki S, Sohara N and Yamazaki Y (2008): Elevated plasma resistin concentrations in patients with liver cirrhosis. J gastroenterology & Hepatology vol 23, 1, 73-77

Kamal SM (2008): "Acute hepatitis C: a systematic review". The American Journal of Gastroenterology 103 (5): 1283–97

Kaplan LM (1998): Leptin, obesity, and liver disease. Gastroenterology 1998;115:997–1001

Khattab M, Ferenci P, Hadziyannis S, Colombo M, Manns M., Almasio P., Esteban R, Abdo A., Harrison S., Ibrahim N, Cacoub P., Eslam M and Lee S (2011): Management of hepatitis C virus genotype 4: Recommendations of An International Expert Panel. Journal of Hepatology Volume 54, Issue 6, Pages 1250-1262

Keam S and Cvetkovic R (2008): Peginterferon alpha-2a (40 KD) plus ribavirin: a review of its use in the management of chronic hepatitis C mono-infection. Drugs, 68: 1273-317.

Kiyosawa, K. Tanaka and Sodeyama (1994): Gastroenterology 106:1596-1602

Kleiner DE (2005): The liver biopsy in chronic hepatitis C: a view from the other side of the microscope. Semin Liver Dis 2005; 25: 52–64.

Kugelmas M, Hill DB, Vivian B, Marsano L and McClain CJ (2003): Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E. Hepatology 38:413–419

Kuo G, Choo QL and Alter HJ (1989): "An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis". Science 244 (4902): 362–4

Kusminski C, McTernan P and Kumar S (2005): Role of resistin in obesity, insulin Resistin and type 2 Diabetes. *Clinical science* 109, 243-256

Lavanchy D (1999): Global Surveillance and Control of Hepatitis C. *J Viral Hepat*, 6:35-47.

Lazar MA (2007): "Resistin- and Obesity-associated metabolic diseases". *Horm. Metab. Res.* 39 (10): 710-6.

Lee, J. H., Bullen, Jr, J.W., Stoyneva, V. L. and Mantzoros, C. S. (2005): Circulating resistin in lean, obese and insulin-resistant mouse models: lack of association with insulinemia and glycemia. *Am. J. Physiol. Endocrinol. Metab.* 288, E625-E632

Lee, J. H., Chan, J. L. and Yiannakouris, N. (2003): Circulating resistin levels are not associated with obesity or insulin resistance in humans and are not regulated by fasting or leptin administration: cross-sectional and interventional studies in normal, insulin-resistant, and diabetic subjects. *J. Clin. Endocrinol. Metab.* 88,4848-4856

Lehrke M, Reilly MP, Millington SC, Iqbal N, Rader DJ, and Lazar MA. (2004): An inflammatory cascade leading to hyperresistinemia in humans. *PLoS Med* 1: e45, 2004.

Lefkowitz H (1996): A textbook of liver disease edited by David Zakim, Thomas:D-Boyer, 3rd edition, 844: 71.

Liaw YF, Sung JJ and Chow WC (2004): Cirrhosis Asian Lamivudine Multicentre Study Group. Lamivudine for patients with chronic hepatitis B and advanced liver disease. *N Engl J Med* 351: 1521–31.

Lin SY, Sheu WHH, Chen WY, Lee FY, and Huang CJ. (2005): Stimulated resistin expression in white adipose of rats with bile duct ligation-induced liver cirrhosis: relationship to cirrhotic hyperinsulinemia and increased tumor necrosis factor-alpha. *Mol Cell Endocrinol* 232: 1–8

Lok AS and McMahon BJ (2004): Practice Guidelines Committee, American Association for the Study of Liver Diseases (AASLD). Chronic hepatitis B: update of recommendations. *Hepatology* 39: 857–61.

Lu SC, Shieh WY, Chen CY, Hsu SC and Chen HL (2002): "Lipopolysaccharide increases resistin gene expression in vivo and in vitro". *FEBS Lett.* 530 (1-3): 158–62.

Macedo de Oliveira, A., Kathryn L. White, Brady D. Beecham; Dennis P. Leschinsky, Brett P. Foley, Janel Dockter, Cristina Giachetti and Thomas J. Safranek (2006): *Journal of Clinical Virology* 35 21–25.

Makimura, H., Mizuno, T. M., Bergen, H. and Mobbs, C. V. (2002): Adiponectin is stimulated by adrenalectomy in ob/ob mice and is highly correlated with resistin mRNA. *Am. J. Physiol. Endocrinol. Metab.* 283,E1266–E1271

Manns MP, Foster G and Rockstroh J (2007): The way forward in HCV treatment. Finding the right path. *Nat Rev Drug Discov*, 6: 991-1000.

Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M and Reindollar R (2001): Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. *Lancet* 2001; 358: 958–965.

Marc G. Ghany, Doris B. Strader, David L. Thomas, Leonard B. Seeff (2009): Diagnosis, management, and treatment of hepatitis C: An update *Hepatology*, Volume 49, Issue 4, pages 1335–1374

Marx M, Murugavel K and Tarwater P (2003): Association of hepatitis C virus infection with sexual exposure in Southern India. *Clin Infect Dis*, 37: 514-20.

Mast E, Hwang L and Seto D (2005): Risk factors for perinatal transmission of hepatitis C virus (HCV) and the natural history of HCV infection acquired in infancy. *J Infect Dis*, 192: 1880-89.

Mazur W, Kulka M and Benlowski M (2010): Resistin, leptin and ghrelin serum levels among the patients with chronic hepatitis C. *Experimental and clinical Hepatology* 2010, 6 (4-3), 17-24

McGovern BH, Wurcel A, Kim AY (2006): "Acute hepatitis C virus infection in incarcerated injection drug users". *Clinical Infectious Diseases* 42 (12): 1663–70.

McTernan, C. L., McTernan, P. G., Harte, A. L., Levick, P. L., Barnett, A. H. and Kumar, S. (2002): Resistin, central obesity, and type 2 diabetes. *Lancet* 359, 46–47

McTernan, P. G., Fisher, F. M. and Valsamakis, G. (2003): Resistin and type 2 diabetes: regulation of resistin expression by insulin and rosiglitazone and the effects of recombinant resistin on lipid and glucose metabolism in human differentiated adipocytes. *J. Clin. Endocrinol. Metab.* 88, 6098–6106

Milan G, Granzotto M, Scarda A, Calcagno A, Pagano C, Federspil G and Vettor R (2002): "Resistin and adiponectin expression in visceral fat of obese rats: effect of weight loss". *Obes. Res.* 10 (11): 1095–103.

Millward-Sadler GH, Hahn EG and Wright R. (1985): Cirrhosis: An appraisal. In: *Liver and biliary disease. Pathophysiology, diagnosis, management.* 2nd edition. Edited by Wright R, Millward-Sadler GH, Alverti KGMM, Karran S. London, Baillière Tindall W.B. Saunders Company 1985:821.

Mohamed MK (2004): Epidemiology of HCV in Egypt. *The Afro-Arab Liver Journal*, 3(2): 41-52.

Morace C, Spadaro A, Cucunat M, Tortorella V, Consolo P, Luigiano C, Stabile G, Bonfiglio C, Bellerone R, Fortiguerra A, Alibrandi A, Crinò S, Carducci A, Resta M L, Ferrau O and Freni M A. (2010): High serum resistin in chronic viral hepatitis is not a marker of metabolic disorder. *Hepatogastroenterology* 57(102-103):1215-9

Monegal A, Navasa M, Gualabens N, Peris P, Pons F, Martinez de Osaba MJ, Rimola A, Rodés J and Muñoz-Gómez J. (1997): Osteoporosis and bone mineral metabolism disorders

in cirrhotic patients referred for orthotopic liver transplantation. *Calcif Tissue Int* 1997;60:148-154.

Müller MJ, Böker KHW, and Selberg O. (1994): Metabolism of energy-yielding substrates in patients with liver cirrhosis. *Clin Investig* 72: 568–579

Murad A, MD Hassan H, MD Husein H, MD and Ayad A, MD (2010): Serum resistin levels in nonalcoholic fatty liver disease and their relationship to severity of liver disease. *JEMDSA* 2010 Volume 15 Number 1.

Nagaev I, Bokarewa M, Tarkowski A and Smith U (2006): Human Resistin Is a Systemic Immune-Derived Proinflammatory Cytokine Targeting both Leukocytes and Adipocytes. *PLoS ONE* 1(1): e31.

Nguyen MH and Keefe EB. (2005): Prevalence and treatment of hepatitis C virus genotypes 4, 5, and 6. *Clin Gastroenterol Hepatol*. 2005;3(Suppl. 2):S97–S101.

Pagano C, Marin O, Calcagno C, Schiappelli C, Pilon C, Milan G, Bertelli M, Fanin E, Andrighetto G, Federspil G, and Vettor R (2005): Increased serum resistin in adults with Prader-Willi syndrome is related to obesity and not to insulin resistance. *J Clin Endocrinol Metab* 90:4335–4340

Pagano C, Soardo G, Pilon C, Milocco C, Basan L, Milan G, Donnini D, Faggian D, Mussap M, Plebani M, Avellini C, Federspil G, Sechi L and Vettor R (2006): Increased Serum

Resistin in Nonalcoholic Fatty Liver Disease Is Related to Liver Disease Severity and Not to Insulin Resistance. The Journal of Clinical Endocrinology & Metabolism Vol. 91, No. 3 1081-1086

Pang, S and Le, Y. (2006): Role of Resistin in Inflammation and Inflammation-Related Diseases, vol 3 number 1' cellular and molecular immunology

Patel Saurabh D., Michael W. Rajala, Luciano Rossetti, Philipp E. Scherer and Lawrence Shapiro (2004): Disulfide-Dependent Multimeric Assembly of Resistin Family Hormones Science 21 Vol. 304. no. 5674, pp. 1154 - 1158

Pawlotsky JM, Lonjon I, Hezode C, Raynard B, Darthuy F, and Remire J (1998): What strategy should be used for diagnosis of hepatitis C virus infection in clinical laboratories? HEPATOLOGY; 27: 1700–1702.

Pawlotsky JM. (2002): Molecular diagnosis of viral hepatitis. Gastroenterology ; 122: 1554–1568.

Pawlowska M and Halota W (2007): PEG INF alpha-2a in the treatment of chronic hepatitis C in patients with treatment failure. Przegl Epidemiol, 61: 23-7.

Podolsky DK and Isselbacher KJ. (1998): Cirrhosis and alcoholic liver disease and major complications of cirrhosis. In: Harrison's principles of Internal Medicine 14th edition. Edited by Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JV, Kasper DL, Hauser SL, Longo DL. Published by McGraw-Hill 1998. 1704-1717.

Porpst A, Propst T, Zangerl G, Ofner D, Judmaier G and Vogel W. (1995): Prognosis and life expectancy in chronic liver disease. *Dig Dis Sci* 1995;40:1805-1815.

Poynard T, Bedossa P and Opolon P (1997): Natural history of liver fibrosis progression in patients with chronic hepatitis C. *Lancet* 1997; 349: 825–32.

Quigley EMM. (1996): Gastrointestinal dysfunction in liver disease and portal hypertension: gut-liver interactions revisited. *Dig Dis Sci* 41:557-563.

Rajala, M. W., Qi, Y. and Patel, H. R. (2004): Regulation of resistin expression and circulating levels in obesity, diabetes, and fasting. *Diabetes* 53, 1671–1679

Rangwala SM, Rich AS, Rhoades B, Shapiro JS, Obici S, Rossetti L and Lazar MA (2004): Abnormal glucose homeostasis due to chronic hyperresistinemia. *Diabetes* 53

Reddy G, Dakshinamurthy K and Neelaprasad P (2005): Prevalence of HBV and HCV dual infection in patients on haemo-dialysis. *Indian J Med Microbiol*, 23: 41–43.

Regev A, Berho M, Jeffers LJ, Milikowski C, Molina EG, and Pylsopoulos NT (2002): Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. *Am J Gastroenterol* 2002; 97: 2614–2618.

Rehermann, Barbara. (2009): Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence *J Clin Invest*. Published in Volume 119, Issue 7 ;119(7):1745–1754

Reilly MP, Lehrke M, Wolfe ML, Rohatgi A, Lazar MA and Rader DJ. (2005): Resistin is an inflammatory marker of atherosclerosis in humans. *Circulation* ;111:932-939.

Reiss G and Keeffe EB. (2005): Role of liver biopsy in the management of chronic liver disease: selective rather than routine. *Rev Gastroenterol Disord* 2005; 5: 195–205.

Rockey DC and Bissell DM. (2006): Noninvasive measures of liver fibrosis. *HEPATOLOGY*; 43(Suppl): S113–S120.

Rosenburg, S (2001): Recent advances in the molecular biology of hepatitis C virus. *J Med Biol*; 313: 451-464

Rubbia-Brandt L, Fabris P, Paganin S, Leandro G, Male PJ, and Giostra E (2004): Steatosis affects chronic hepatitis C progression in a genotype specific way. *Gut* 2004; 53: 406–412.

Ruiz JD, Molitor F and Plagenhoef JA (2002): "Trends in hepatitis C and HIV infection among inmates entering prisons in California, 1994 versus 1999". *AIDS* 16 (16): 2236–8. doi: 10.1097/00002030-200211080-00023. PMID 12409752.

Runyon, BA. (1997): Historical aspects of treatment of patients with cirrhosis and ascites. *Semin Liver Dis* 17: 163–73.

Saldanha J, Lelie N and Heath A. (1999): Establishment of the first international standard for nucleic acid amplification technology (NAT) assays for HCV RNA. WHO Collaborative Study Group. *Vox Sang* 1999; 76: 149–158.

Sanchez J, Sjogren M and Callahan J, (2000): Hepatitis C in Peru: risk factors for infection, potential iatrogenic trans-mission, and genotype distribution. *Am J Trop Med Hyg*, 63: 242–48.

Sandrin L, Fourquet B, Hasquenoph JM, Yon S, Fournier C and Mal F, (2003): Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. *Ultrasound Med Biol* 2003; 29: 1705–1713.

Savage, D. B., Sewter, C. P. and Klenk, E (2001): Resistin/Fizz3 expression in relation to obesity and peroxisome proliferator-activated receptor- γ action in humans. *Diabetes* 50, 2199–2202

Scheuer PJ. (1991): Classification of chronic viral hepatitis: a need for reassessment. *J Hepatol* 1991; 13: 372–374.

Schuppan D. and Afdhal N. (2008): Liver cirrhosis, *Lancet* 371: 838–51

She H, Xiong S, Hazra S, and Tsukamoto H. (2005): Adipogenic transcriptional regulation of hepatic stellate cells. *J Biol Chem* 280: 4959–4967, 2005.

Shiffman M, Suter F and Bacon B (2007): Peginterferon α -2a and ribavirin for 16 or wks in HCV in genotype 2 or 3. *N Engl J Med*, 357: 124-34.

Silha, J. V., Krsek, M., Skrha, J. V., Sucharda, P., Nyomba, B. L. and Murphy, L. J. (2003): Plasma resistin, adiponectin and leptin levels in lean and obese subjects: correlations with insulin resistance. *Eur. J. Endocrinol.* 149, 331–335

Silswal N, Singh AK, Aruna B, Mukhopadhyay S, Ghosh S, and Ehtesham NZ (2005): "Human resistin stimulates the pro-inflammatory cytokines TNF-alpha and IL-12 in macrophages by NF-kappaB-dependent pathway". *Biochem. Biophys. Res. Commun.* 334 (4): 1092–101.

Simmonds P (2004): Genetic diversity and evolution of hepatitis C virus -15 years on. *J Gen Virol*, 85:3173-88.

Smith SR, Bai F, Charbonneau C, Janderova L and Argyropoulos G. A (2003): promoter genotype and oxidative stress potentially link resistin to human insulin resistance. *Diabetes* 2003;52:1611–1618.

Spada E, Mele A and Ciccozzi M (2001): Changing epidemiology of parenterally transmitted viral hepatitis: results from the hepatitis surveillance system in Italy. *Dig Liver Dis*, 33: 778-84.

Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima RS and Lazar MA (2001): "The hormone resistin links obesity to diabetes". *Nature* 409 (6818): 307–12.

Steppan CM and Lazar MA. (2004): The current biology of resistin. *J Intern Med* 255: 439–447, 2004.

Stickel F, Schuppan D, Hahn EG and Seitz HK. (2002): Cocarcinogenic effects of alcohol in hepatocarcinogenesis. *Gut* 2002; 51: 132–39.

Strader D, Wright T and Thomas D (2004): Diagnosis, management, and treatment of hepatitis C. *Hepatology*, 39: 1147-71.

Stramer SL, Glynn SA and Kleinman SH (2004): Detection of HIV-1 and HCV infections among antibody-negative blood donors by nucleic acid-amplification testing. *N Engl J Med*; 351:760-68.

Strickland G, El Hefni H, Salman T (2002): Role of hepatitis C infection in chronic liver disease in Egypt. *Am J Trop Med Hyg*, 67: 436-42.

Stuyver L., Wyseur A., Arnhem W (1996): Second-generation line probe assay for hepatitis C virus genotyping. *J Clin Microbiol* 1996;34(9):2259-66.

Szabo E, Lotz G, Paska L and Schaff Z (2003): viral hepatitis; new data on hepatitis C infection. Pathology and oncology Research vol 9, 4, 215-221.

Talley NJ (2008): Gastroenterology and Hepatology: A clinical handbook 2008 Elsevier Australia

Tangerman A, Meuwese-Arends MT and Jansen JB (1994): Cause and composition of foetor hepaticus. Lancet 1994; 343: 483.

Thio CL, Nolt KR, Astemborski J, Vlahov D, Nelson KE, and Thomas DL. (2000): Screening for hepatitis C virus in human immunodeficiency virus-infected individuals. J Clin Microbiol 38: 575–577.

Tiftikci A, Atug O, Yilmaz Y, Eren F, Ozdemir FT, Yapali S, Ozdogan O, Celikel CA, Imeryuz N and Tozun N. (2009): Serum levels of adipokines in patients with chronic HCV infection: relationship with steatosis and fibrosis. Arch Med Res. May;40(4):294-8.

Timm J, Neukamm M and Kuntzen T (2007): Partners AIDS Research Center, Infectious Disease Division, Massachusetts General Hospital, Boston, MA,USA. viral Hepat, 14(5): 330-37.

Tsochatzis E, Papetheodoridis G and Hadziyannis E (2008): Serum adipokine levels in chronic liver diseases. Scandinavian journal of Gastroenterology volume 43, 1128-1136

Valsamakis, G., McTernan, P. G. and Chetty, R. (2004): Modest weight loss and reduction in waist circumference after medical treatment are associated with favourable changes in serum adipocytokines. *Metab. Clin. Exp.* 53,430–434

Vendrell, J., Broch, M. and Vilarrasa, N. (2004): Resistin, adiponectin, ghrelin, leptin, and proinflammatory cytokines: relationships in obesity. *Obes. Res.* 12, 962–971

Verma S, Li SH, Wang CH, Fedak PW, Li RK, Weisel RD and Mickle DA (2003): "Resistin promotes endothelial cell activation: further evidence of adipokine-endothelial interaction". *Circulation* 108 (6): 736–40.

Villano SA, Vlahov D, Nelson KE, Cohn S and Thomas DL (1999): "Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection". *Hepatology* 29 (3): 908–14.

Vojarova de Courten, B., Degawa-Yamauchi, M., Considine, R. V., Tataranni, P. A. and Volarova de Courten, B. (2004): High serum resistin is associated with an increase in adiposity but not a worsening of insulin resistance in Pima Indians. *Diabetes* 53, 1279–1284

Wang H, Chu WS, Hemphill C and Elbein SC (2002): "Human resistin gene: molecular scanning and evaluation of association with insulin sensitivity and type 2 diabetes in Caucasians". *J. Clin. Endocrinol. Metab.* 87 (6): 2520–4.

Wasley A and Alter MJ. Epidemiology of hepatitis C (2000): geographic differences and temporal trends. *Semin Liver Dis.* 20:1-16.

Wasley A, Miller JT and Finelli L (2005): Surveillance for acute viral hepatitis — United States, 2005. MMWR Surveill Summ 2007; 56: 1–24.

Way, J. M., Gorgun, C. Z. and Tong, Q (2001): Adipose tissue resistin expression is severely suppressed in obesity and stimulated by peroxisome proliferator-activated receptor γ agonists. J. Biol. Chem. 276, 25651–25653

Wellen KE and Hotamisligil GS (2005): "Inflammation, stress, and diabetes". J. Clin. Invest. 115 (5): 1111–9.

Westin J, Lagging M, Dhillon AP, Norkrans G, Romero AI and Pawlotsky JM (2007): Impact of hepatic steatosis on viral kinetics and treatment outcome during antiviral treatment of chronic HCV infection. J Viral Hepat 2007; 14: 29–35.

Wong V, Wong G, Yu J (2009): Interaction of Adipokines and Hepatitis B Virus on Histological Liver Injury in the Chinese. Am J Gastroenterol 2010; 105:132–138

World Health Organization (2004): Hepatitis C – Global Surveillance Update. Weekly Epidemiological Record, 75: 17-28.

Workowski KA and Berman SM. (2006): Sexually transmitted diseases treatment guidelines, 2006. MMWR Recomm Rep 2006; 55: 1–94.

Wynn T (2008): Cellular and molecular mechanisms of fibrosis. J Pathol 214:199-210.

Yazdanpanah Y, De Carli G and Miguers B (2005): Risk factors for hepatitis C virus transmission to health care workers after occupational exposure: a European case-control study. Clin Infect Dis, 41: 1423-30.

Ytting H, Møller S, Henriksen JH, Larsen K and Bendtsen F (2006): Prognosis in patients with cirrhosis and mild portal hypertension. Scand J Gastroenterol 41:1446-1453.

Youn BS, Yu KY, Park HJ, Lee NS, Min SS, Youn MY, Cho YM, Park YJ, Kim SY, Lee HK and Park KS (2004): Plasma resistin concentrations measured by enzyme-linked immunosorbent assay using a newly developed monoclonal antibody are elevated in individuals with type 2 diabetes mellitus. J Clin Endocrinol Metab 89:150–156

Zhang, J., Qin, Y. and Zheng, X (2002): The relationship between human serum resistin level and body fat content, plasma glucose as well as blood pressure. Zhonghua Yi Xue Za Zhi 82, 1609–1612